Canada markets closed

Atara Biotherapeutics, Inc. (AT2.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.6516-0.0064 (-0.97%)
At close: 09:11AM CEST
Full screen
Previous Close0.6580
Open0.6516
Bid0.6668 x N/A
Ask0.6786 x N/A
Day's Range0.6516 - 0.6516
52 Week Range0.1795 - 2.7450
Volume400
Avg. Volume1,985
Market Cap78.131M
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-2.4300
Earnings DateMay 06, 2024 - May 10, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.38
  • Business Wire

    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    THOUSAND OAKS, Calif., April 05, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Bi

  • Zacks

    Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates

    Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 8.20% and 73.91%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

    THOUSAND OAKS, Calif., March 28, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2023, recent business highlights, and key upcoming milestones for 2024.